Coordinated by GU Ventures
GU Ventures welcomes and appoints Eduarde Rohner as Lead for New Modality Support
As of November 1, Eduarde Rohner is the Lead for New Modality Support (NMS), a forward-looking initiative in collaboration with the Sahlgrenska Academy, the medical faculty at the University of Gothenburg, and the Sahlgrenska University Hospital. The aim is to support the commercial development of research projects within the national pharmaceutical initiatives OligoNova and CCRM Nordic.
Eduarde Rohner, who holds a PhD in Medical Sciences, brings extensive experience in the development of stem cell and mRNA therapies, where he has contributed to advancing therapeutic assets from early discovery to preclinical proof-of-concept. In his previous role as Senior Scientist at SmartCella Solutions, Eduarde also established landscape analysis and strategies for patentability.
“I am pleased to have been appointed Lead for NMS. This role allows me to leverage my experience gained from managing projects within stem cell and mRNA therapies, as well as from my research conducted during my doctoral studies at the Karolinska Institute, in a new context. I look forward to working with our partners and the NMS team to create new and competitive global companies”, says Eduarde Rohner.
“Eduarde brings valuable experience and a strong network to develop and commercialize individual research projects within NMS, which offers support and serves as a platform of expertise as projects transition from academic research to clinical application”, says Carl-Peter Mattsson, Investment Director at GU Ventures and Strategic Coordinator for NMS.
About New Modality Support (NMS)
NMS supports the further development and commercialization of individual research projects within the therapeutic oligonucleotide and ATMP sectors. By combining the experience and resources of participating parties with new, sector-specific expertise, value-creating services can be developed and deployed more efficiently. Additionally, as a platform that promotes networking and highlights both the research and commercialization efforts, NMS enhances opportunities for projects and companies to attract investments and partnerships.
NMS is located at GoCo Health Innovation City in Mölndal and is supported by both the Västra Götaland Region through the Environment and Regional Development Board, as well as by the University of Gothenburg and GU Ventures. This support enables GU Ventures, the coordinator for NMS, to work strategically and sustainably towards the project´s success.
For more information, please visit:
For additional information, please contact:
Carl-Peter Mattsson, Investment Director, GU Ventures
Phone: +46(0)708699354
Email: carl-peter@ventures.gu.se
